Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.
Eur Heart J. 2012 Mar;33(6):791-9. doi: 10.1093/eurheartj/ehr145. Epub 2011 May 30.
Accumulating evidence indicates that coronary vasoconstricting responses are enhanced at the edges of coronary segment implanted with a drug-eluting stent (DES) compared with a bare-metal stent (BMS) in humans. We have recently demonstrated that Rho-kinase pathway plays an important role in DES-induced coronary hyperconstricting responses associated with inflammatory changes in pigs in vivo. This study examined whether long-term treatment with calcium channel blocker suppresses DES-induced coronary hyperconstricting responses in pigs in vivo.
Paclitaxel-eluting stent (PES) and a BMS were randomly implanted in the left coronary arteries in male domestic pigs with and without long-acting nifedipine (NIF, 4 mg/kg/day) for 4 weeks (n = 7 each). Coronary vasomotion was evaluated by quantitative coronary angiography at least 24 h after withdrawal of NIF to avoid its direct effects on coronary vasomotion. In the control group (without NIF), coronary vasoconstricting responses to serotonin (10 and 100 µg/kg, i.c.) were significantly enhanced at the PES site compared with the BMS site (P = 0.009), which were abolished by hydroxyfasudil (90 and 300 µg/kg, i.c.), a selective Rho-kinase inhibitor. The PES-induced vasoconstricting responses were significantly inhibited in the NIF group (P = 0.019). Histological examination showed that inflammatory cell accumulation and microthrombus formation were enhanced at the PES site compared with the BMS site (P < 0.05), both of which were significantly suppressed by NIF associated with reduced Rho-kinase expression and activity (P < 0.05).
These results indicate that long-term treatment with NIF suppresses PES-induced coronary abnormalities partly through Rho-kinase pathway inhibition in vivo.
越来越多的证据表明,与裸金属支架(BMS)相比,在人体中,药物洗脱支架(DES)植入的冠状动脉节段边缘的冠状动脉收缩反应增强。我们最近的研究表明,Rho 激酶通路在体内猪 DES 诱导的冠状动脉强烈收缩反应及其相关炎症变化中起着重要作用。本研究旨在探讨长期应用钙通道阻滞剂是否能抑制体内猪 DES 诱导的冠状动脉强烈收缩反应。
雄性家猪的左冠状动脉内随机植入紫杉醇洗脱支架(PES)和 BMS,其中一组同时给予长效硝苯地平(NIF,4mg/kg/天)治疗 4 周(每组 7 只)。在停用 NIF 至少 24 小时后,通过定量冠状动脉造影评估冠状动脉舒缩运动,以避免其对冠状动脉舒缩运动的直接影响。在对照组(无 NIF)中,与 BMS 部位相比,PES 部位对 5-羟色胺(10 和 100μg/kg,ic)的冠状动脉收缩反应明显增强(P=0.009),而 Rho 激酶选择性抑制剂羟甲噻嗪(90 和 300μg/kg,ic)可消除这种增强作用。NIF 组 PES 引起的血管收缩反应明显受到抑制(P=0.019)。组织学检查显示,与 BMS 部位相比,PES 部位炎症细胞聚集和微血栓形成明显增加(P<0.05),NIF 可显著抑制这些反应,同时降低 Rho 激酶的表达和活性(P<0.05)。
这些结果表明,长期应用 NIF 通过抑制 Rho 激酶通路,可部分抑制体内 PES 引起的冠状动脉异常。